ライフサイエンスコーパス: ecto-5'-nucleotidase

1 PAP suppresses pain by functioning as an ecto-5'-nucleotidase.

2 ition is mediated by selective inhibition of ecto-5'-nucleotidase.

3 rch for potential targets of zinc other than ecto-5'-nucleotidase.

4 serial actions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

5 e feedforward ADP-mediated inhibition of the ecto-5'-nucleotidase.

6 The adenosine producing enzyme ecto-5'-nucleotidase (5'-NT) is not normally expressed d

7 NTPD; cluster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

8 These results not only show that ecto-5'-nucleotidase activity is a critical mediator of

9 The NudP ecto-5'-nucleotidase activity is reminiscent of the reac

10 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP brea

11 recombinant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucl

12 ,beta-methylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+)

13 ice lacking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellul

14 This study tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conve

15 ow that NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosin

16 bolism, adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adeno

17 of fibroblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

18 but not with this solution plus a blocker of ecto-5'-nucleotidase (AOPCP).

19 eletal muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

20 he expression of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD3

21 ation in the supernate of cells deficient in ecto-5'-nucleotidase, but there is a marked increase in

22 extracellular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after

23 generates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

24 An inhibitor of the ecto-5'-nucleotidase CD73, alpha, beta-methylene ADP (AO

25 nd the immunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

26 ] to adenosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

27 known as "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhi

28 on selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

29 etabolized to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates s

30 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosp

31 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step

32 Production of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial b

33 nce staining, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive ne

34 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid bod

35 Ecto-5'-nucleotidase (CD73) is a central surface enzyme

36 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for

37 Ecto-5'-nucleotidase (CD73) is central to the generation

38 Ecto-5'-nucleotidase (CD73) is expressed abundantly on t

39 Ecto-5'-nucleotidase (CD73) is the main enzyme responsib

40 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extra

41 mechanism, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

42 Ecto-5'-nucleotidase (CD73) on immune cells is emerging

43 lammatory response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart

44 1; CD39) to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

45 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in co

46 hosphate (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to th

47 in CA1 than in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

48 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts ext

49 The present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates ad

50 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the maj

51 role of the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and or

52 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of e

53 Ecto-5'-nucleotidase (CD73), the enzyme that generates a

54 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to co

55 osine-monophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contributio

56 activity of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly low

57 e triphosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

58 by the terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

59 feedback) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme resp

60 riphosphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas,

61 ate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 22

62 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-d

63 oustic stimuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A

64 pression of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(

65 more potent against c-N-I than the membrane ecto-5'-nucleotidase (e-N).

66 mediated the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline pho

67 ytosolic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase (ecto-5'-NT).

68 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-boun

69 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis

70 1(high) cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

71 high) subset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence

72 ytosol, while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

73 te (AMP-CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did

74 test the role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

75 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog

76 have directly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

77 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene ade

78 etreated cells to activated neutrophils; the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ade

79 orescent beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP

80 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP

81 ignal was greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP

82 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significa

83 by 40.4 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellu

84 of inflammation, and injection of APCP, the ecto-5'-nucleotidase inhibitor, abrogates completely the

85 to adenosine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene ade

86 leoside transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine signi

87 3 in EPEC infection by testing the effect of ecto-5'-nucleotidase inhibitors.

88 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosi

89 We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and establish

90 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation fr

91 of evidence that adenosine results from the ecto-5'-nucleotidase- mediated conversion of adenine nuc

92 t Group B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and

93 ggest that specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor act

94 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP

95 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in

96 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored

97 or (A(2B)R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phos

98 aste stimulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, pros

99 tic triglyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors we

100 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulat

101 bs that target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors an

102 ificantly facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

103 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phospho

104 bition by the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine intr

105 used mice that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to